AIM: - To describe baseline characteristics and safety data of real-world use of semaglutide 2.4 mg. METHODS: - Patients with a body mass index (BMI) ≥40 kg/m RESULTS: - Overall, 5,797 (62.8%) treatment requests were sent by sites specialized in obesity management. In total, 478 and 8,568 patients were treated within TUA and EAP cohorts respectively, with mean follow-up durations of 1.2 and 4.5 months, respectively. Mean (SD) BMI was 48.9 (9.7) and 47.0 (7.4) kg/m CONCLUSION: - The high number of treatment prescriptions in a short period highlights the high unmet medical need. No new safety concerns were identified in this population with severe obesity treated in a real-world setting.